Transdermal analgesic patch

The main purpose of transdermal analgesic patches are to administer drugs in a more viable way to patients, as opposed to oral consumption or intravenous administration such as an injection.

[1] Counterirritant patches contain ingredients such as capsaicin, methyl salicylate, camphor, or menthol, which are thought to mask pain signals by causing other sensations (itching, warmth, or cooling) in the areas they are applied to.

[2] In the United States, patches sold under the brand name Salonpas are approved by the Food and Drug Administration under a New Drug Application (NDA) for the treatment of mild to moderate pain caused by soft tissue injury (e.g., strains, sprains), arthritis, or backache.

Other over-the-counter products marketed for the relief of minor injury or arthritis pain include Absorbine Jr.

They are approved for sale over-the-counter for the treatment of mild pain caused by soft tissue injury (e.g., strains, sprains), arthritis, or backache.

Sherman Kramer and Dale Wurster, his teacher, were both based in pharmacology and are credited with the beginning stages of transdermal patch delivery in 1961.

Arnold Beckett, a British pharmacist, held experiments with a patch system that were studied and proven to maintain steady blood levels through administration of the drug.